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Abstract
This study aimed to determinewhether there is a persistentor differenttype of airway inflammation in patientswith an
incomplete reversibility of airflow obstruction (IRAO) despite optimal treatment and if so, whether it is associatedwith
an accelerateddecline ofpulmonary function.Fifteen asthmaticpatientswith IRAO, and 23withcompletereversibilityof
airflowobstruction (CRAO) had a spirometryand aninduced-sputum (IS) analysis.Past FEV1valueswererecorded over
2^12 years during periods of stable asthma.Medians (range) for IS cell differentialswere: lymphocytes, 0(0^3)/1(0^2)%;
neutrophils, 56(13^88)/38(3^84)% and eosinophils, 2.0(0^82)/4.0(0^68)%, (all P40.05). Among non-smoking patients,
those with IRAOhadmore neutrophils in IS than those with CRAO (P=0.019).Mean (7SEM) yearly fall in FEV1 in IRAO
or CRAO patients was 54721/84716ml/year (P40.05, predicted age-related decliner26ml/year, P=0.0008). In the
whole group of asthmatic patients, decline of FEV1/year was inversely correlated with the % neutrophils in sputum
(rs=0.436, P=0.008) and, in IRAOpatients, with the duration of asthma (rs=0.559, P=0.037). In conclusion, persistent
airwayinflammationandincreaseddeclineinpulmonary functioncanbeobservedinbothasthmaticpatientswith IRAO/
CRAO and are of similar magnitude.Non-smoking patients with IRAO hadmore neutrophils in IS than CRAO. r 2003
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Our understanding of the psychopathology of asthma
has increased markedly over the last two decades, and
the role of airway in£ammation in the development of
airway hyperresponsiveness (AHR) and symptomatic
asthma has been highlighted (1^3). Airway function
changes in asthmamayresult from in£ammation-induced
airway structural changes (4^5).Thebronchial in£amma-
tory and remodeling processes may lead to air£ow ob-
struction and airway hyperresponsiveness although
their contribution to persistent AHRor air£ow obstruc-
tion, and to the accelerated decline in pulmonary func-
tion observed in asthma, remain to be de¢ned (6^8).
Asthma may sometimes be associatedwith an incom-
plete reversibility of air£ow obstruction (IRAO), even
with optimal corticosteroid treatment, a condition often
confounded with smoking-induced chronic obstructive
pulmonary disease (COPD) (9). A comparison of clinical,
physiological and radiological features of these two last$Supportedby the Asthma Society of Canada
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struction may be relatively similar, the underlying asso-
ciated features are quite di¡erent (10^12). COPD has
been associated with an airway neutrophilic in£amma-
tion, a lesser response to anti-in£ammatory treatment
and accelerated decline in pulmonary function (13); it
would be also of interest to determine if some of those
features also exist in asthma with IRAO. The present
study was designed to compare patients with IRAO, as
de¢ned by an FEV1o75% of the predicted value despite
optimal treatment, and asthmatic patients with com-
pletereversibilityof air£owobstruction, for clinical char-
acteristics, induced sputum cell counts and decline in
pulmonary function (14).
METHODS
Patients
Patients with at least 2 years of previous records of pul-
monary function tests, either in hospital or at the re-
search laboratory and agreeing to the proposed
investigation were recruited. All patients ful¢lled the
American Thoracic Society criteria for asthma and had
shown reversibility of air£ow obstruction as assessed by
TABLE 1. Patients’characteristics.
IRAO CRAO
Numberof patients 15 23
Gender (F/M) 9F/6M 10F/13M
Age inyears (mean7SEM) 5573 5173
Atopy (n) 13 19
Duration of asthma 32.875.0 19.572.7
(meanyears7SEM)
Baseline FEV1 (% of predicted) 5673 9374
(mean7SEM)
Ex-smokers (n) 6 6
Numberof years of
cessation of smoking
23.7 21.2
(mean, range) (3^36 years) (5^36 years)
Pack-years 3.9 4.0
(mean, range) (0.5 ^8) (0.2^7.5)
Prednisone users (n) 2 1
Inhaled corticosteroids 11177136 8397115
(equivalence in mg
beclomethasone/day)
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after bronchodilator (1,15) IRAO was de¢ned by an FEV1
o75% of the predicted value despite optimal treatment
evenduring a period of treatmentwith high-dose inhaled
corticosteroids or with a brief course of oral steroids.
Asthmatic patients were considered to have complete
reversibility of air£ow obstruction (CRAO), if their
FEV1 reached480% spontaneously or after treatment.
Pulmonary function had been recorded at variable inter-
vals, with the number of measurements going from one
every two years up to one per year in the last 5 years or
for a longer period of time.We excluded patients with
contraindications to the proposed evaluation, previous
or current history of signi¢cant systemic or pulmonary
disease other than asthma, contraindications to the pro-
posed tests or unstable respiratory conditions. Smokers
and ex-smokers of 410 pack-years were also excluded.
The study was approved by our institution’s ethics com-
mittee, and all patients signed informed consent forms.
Study design and evaluation
On their visit, patients ¢lled out a questionnaire on their
respiratory and general health. Expiratory £ows were
measured and their reversibility after bronchodilator
was assessed. If not recorded in the previous 3 years, al-
lergy skin-prick tests were done with a battery of com-
mon aeroallergens. A chest radiographwas obtained for
all patients, if not available from the previous 5 years, to
exclude other respiratory conditions. All patients also
had induced-sputum analysis. The validated respiratory
questionnaire included questions about the patients’
characteristics, smoking, duration and control of asthma
and its treatment, including the nature and intensity of
the respiratory symptoms, exposure to potential asth-
ma-triggering factors (allergens, etc.), medication needs
and associated health problems.
A retrospective analysis of patients’ previous records
of pulmonary function tests was performed for the last
2^12 years (mean of 6.8 and 5.7 years in IRAOandCRAO
patients, respectively, P40.05) to document changes in
post-bronchodilator FEV1 over time, when the patient
was in stable condition. The highest FEV1 of the year
was considered.The fall in FEV1over timewas calculated
on a ‘‘per year’’ value.The decline in FEV1was estimated
from the di¡erence in absolute value of FEV1 over the
years between two FEV1 measurements and the di¡er-
ence between predicted age-related values over the
same period; it was expressed as a ‘‘per year’’ value.The
mean of all ‘‘per year’’ values was calculated.
Pulmonary function tests included three reproducible
measurements of FEV1 and forced vital capacity (FVC)
before and after inhalation of salbutamol (200mg) ac-
cording to a standardized procedure. Measurements
were obtained with a spirometer responding to the cri-teria of theAmericanThoracic Society (16).Predicted va-
lues were obtained from Knudson (17).
Allergy skin-prick tests were performed with a bat-
tery of common allergens including animals, dust and
housedust mites, pollens and molds. Atopic status was
de¢ned as the presence of at least one positive reaction
(wheal diameter 3mm ormore) 10min after testing.
Sputumwas obtained and analyzed using the method
described by Pin et al., as modi¢ed by Pizzichini et
al.(18,19).
Analysis
Results are expressed asmean7SEM for FEV1and asmed-
ians for sputum cell di¡erentials. Predicted values from
Lange et al. were used for annual decline of pulmonary
function (8,17). The percent fall of FEV1 over time (per
year) and the D decline of FEV1 (observed minus pre-
dicted) per year were compared in the two groups stu-
died.The comparison of the cell di¡erential on induced-
sputum was done between the two groups using non-
parametric tests.
RESULTS
We evaluated 15 asthmatic patients with IRAO and 23
asthmatic patients with CRAO (Table 1). Patients with
IRAO (9F/6M) were aged 24^70 years; 13 were atopic.
Duration of asthma ranged from 6 to 63 years (mean:
32.8). They were nine non-smokers and six ex-smokers
who had not smoked forX1year (mean: 3.9 pack-years).
All showed a persistence of air£ow obstruction as
demonstrated by an FEV1o75% of the predicted value
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high dose inhaled). These patients had neither a history
nor anyevidence of pulmonarydisease that could explain
the irreversibility of air£ow obstruction. All were on in-
haled corticosteroids. Characteristics of patients with
CRAO are found inTable1.
Pulmonary function anddecline over time
On their visit to the laboratory, patients’ mean baseline
FEV1 was 5673% in IRAO patients and 9374% in
CRAO. Mean yearly fall in FEV1was 54721ml in IRAO
and 84716ml in CRAO patients (P40.05), while pre-
dicted age-related FEV1 declines in the two groups
(7SEM) were 2472 and 2671ml, respectively, for a
mean di¡erence (D decline) of 30722ml (median:
30ml) in IRAO and of 58716ml (35ml) in CRAO
(P40.05).The observed decline in FEV1was greater than
the predicted age-related decline for both groups
(P=0.0008). No signi¢cant di¡erences were observed in
FEV1/year between non-smokers and ex-smokers o10
pack-years or between genders, in either IRAO or
CRAO patients (Fig. 1). The decline of FEV1/year was of
the samemagnitude in atopic (74715ml/year, n=32) and
non-atopic patients (61715ml/year, n=6) for a D decline
of FEV1of 49715ml/year in atopics and of 37716ml/year
in non-atopics (P40.05).
Induced-sputumcell analysis
Percent eosinophils, neutrophils and epithelial cells in
sputum were higher both in IRAO and CRAO patientsFIG. 1. Observed and predicted decline of FEV1/year (A) and Dde
the decline or Ddecline of FEV1/year betweennon-smokers or ex-sin comparison with the predicted values suggested for
thismethodby Pizzichini et al. (Fig. 2).Therewere no sig-
ni¢cant di¡erences between IRAO and CRAO patients
in the sputumpercentages (median %, range) of lympho-
cytes (Table 2).When non-smokers and ex-smokerso10
pack-yearswere comparedin IRAOandCRAOgroups, a
signi¢cant di¡erence was observed between IRAO and
CRAO non-smoker-patients for neutrophils (56 and
36%, P=0.019); the other cell counts were similar in the
two groups.
Correlations between decline in pulmonary
function, durationof asthma, dose of inhaled
corticosteroids, in£ammatory cells in
sputumand smoking history
The decline of FEV1/year was not correlated with age;
however, it was inversely correlated with the duration
of asthma in IRAOpatients (rs=0.559,P=0.037).The de-
cline of FEV1/year was not signi¢cantly correlated with
the number of years elapsed since the beginning of its
measurement (P40.05). No signi¢cant correlation was
found between the decline of pulmonary function and
the dose of inhaled corticosteroids prescribed, nor with
the percentage of lymphocytes or eosinophils in sputum.
However, there was a negative correlation between the
D decline of FEV1/year and the% neutrophils (all patients:
rs=0.438, P=0.008, CRAO patients: rs=0.581,
P=0.007). Among CRAO patients, the correlation was
signi¢cant in non-smokers only (rs=0.708, P=0.005; ex-
smokerso10 pack-years: rs=0.143,P=0.75).Therewere
no signi¢cant correlations between the dose of inhaledcline of FEV1/year (B).No signi¢cantdi¡erenceswere observed in
mokers or between IRAOor CRAOpatients
FIG. 2. Induced-sputum cell di¡erentials of IRAO and CRAO patients. In£ammatory cells were distributed similarly in IRAO and
CRAOpatients although non-smoking patientswith IRAOhadmore neutrophils than non-smoking patientswith CRAO.Medians of
the% eosinophils, neutrophils andepithelialcellsin sputumwerehigher thanrangesofnormalvalues (shadedareas).Withineachgroup,
cell countswere not signi¢cantlydi¡erent betweennon-smokers and ex-smokers.
TABLE 2. Medians of induced-sputum cell di¡erentials in
IRAOand CRAOpatients.
IRAO CRAO
(n=15) (n=23)
Lymphocytes (%) 0 1
Range 0^3 0^2
Macrophages (%) 23 50
Range 5^80 4^92
Neutrophils (%) 56 38
Range 13^88 3^84
Eosinophils (%) 2.0 4.0
Range 0^82 0^68
742 RESPIRATORYMEDICINEcorticosteroids and thenumberof neutrophils or eosino-
phils (P40.05).The fall in FEV1/year was positively corre-
lated with the smoking history, expressed in pack-years
(all patients: rs=0.720, P=0.017, IRAO patients: rs=0.943,
P=0.017), but no correlation was found with the number
of years since patients had quit smoking.
DISCUSSION
IRAO and CRAO patients showed a similar and acceler-
ated reduction in pulmonary function compared with
predicted values. Most patients with IRAO and CRAO
showed persisting airway in£ammation with increased
neutrophil and eosinophil numbers, similar towhat is re-ported in the general asthmatic population (19). Non-
smoking patients with IRAO had however more neutro-
phils in IS than those with CRAO.There was no signi¢-
cant correlation between eosinophils in sputum and the
observed reduction in pulmonary function, but there
was a negative correlation between the % neutrophils in
sputum and the reduction in pulmonary function in non-
smoker CRAOpatients. In ex-smokers, a positive corre-
lation was observed with IRAO between the reduction
in pulmonary function and smoking history (pack-years).
The yearly decline of FEV1 observed in IRAO and
CRAO was more marked in our patients than the de-
cline observed by Lange et al. in asthmatic patients
(27ml in non-smokers and 44ml in smokers) (8).The dif-
ference between the two studies may be explained, at
least partially, by the di¡erent number of measurement
to calculate the yearly decline of FEV1, the degree of se-
verity of asthma, and the smaller sample size in our
study. Although the di¡erencewas not statistically signif-
icant, IRAO patients showed a slower decline in FEV1
than CRAO patients. Our retrospective analysis of de-
cline in FEV1mayhowever have startedwhen pulmonary
function had already declined more in IRAO than in
CRAOpatients.
The decline in FEV1in our group of asthmatic patients
is intermediate between normal pulmonary condition
and COPD (8).We do, however, need more studies on
mild vs more severe asthma populations and on the
causes of accelerated decline and of the development of
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matic patients who had a steeper yearly decline of FEV1
and developed non-reversible air£ow obstruction after
10 years (20).
As observed in previous reports, the decline of FEV1
was not correlated with the age of the patients (21,22).
The negative correlation between duration of asthma
and decline of FEV1in IRAO patients is, however, in con-
tradiction with the report of Brown et al., who showed
that the degree of airwayobstructionwas positively cor-
related with the duration of previous asthma (10). How-
ever, a more marked decline in FEV1 had been reported
in patients with newly diagnosed asthma comparedwith
patients with long-standing asthma, whose decline of
FEV1 did not di¡er from that of non-asthmatic patients
(23).Factors other thanduration of asthma, such as time
of onset of the disease, presence of atopy, severity of
asthma or smoking history, and events that led to the ir-
reversibility of air£ow obstruction may have in£uenced
the rate of decline of FEV1and could possibly explain the
di¡erences observed between reports.
Induced-sputum cell di¡erential in IRAO and CRAO
patients was within the ranges previously measured in
19 stable asthmatic patients (19).The lack of di¡erence in
in£ammatory cell counts between the whole group of
patients with IRAO and CRAO could be explained by
the similarity of the patients in the two groups; they had
similar medication needs, most were atopic; ex-smokers
had a similar history of smoking. The higher number of
neutrophils in non-smoking patients with IRAO, com-
pared to non-smoking patients with CRAO, is however
of interest and may suggest a di¡erent in£ammatory
pro¢le, possibly more ‘‘resistant’’ to corticosteroids, as
in COPD (15). Besides, Little et al. demonstrated that
the duration of asthma was related to a higher percen-
tage of neutrophils in sputum, suggesting that these cells
re£ect the chronicity of the disease (24). The fact that
non-smoking IRAO patients had a longer duration of
asthma than non-smoking CRAO patients is in agree-
mentwith this.
A correlationwas observedby Stanescu etal. between
increased levels of sputum neutrophils and rapid decline
in FEV1in smokers and ex-smokers over a15-year follow-
up period (25). The negative correlation that we found
between sputum neutrophils and % decline of FEV1 did
not appear, however, to be a consequence of the use of
ICS, since therewas no signi¢cantcorrelationbetween%
neutrophils in induced sputum and the dose of ICS.
We observed, in CRAO only, a correlation between
the number of macrophages and the decline in pulmon-
ary function.These cells have thepotential tobe involved
as modulators of response to the treatment and to be
involved in the airway remodeling process (26).Mautino
et al. showed that the imbalance of MMP-9 and TIMP-1
production observed in asthma, via the involvement of
di¡erentcytokines, suggested that alveolarmacrophagesmay be involved in the abnormal repair observed in
chronic asthma (27).
Finally, we should point out that as induced-sputum
analysis was done at only one time-point in the natural
history of the disease of our patients, usually when the
condition was stable under regular therapy, it may pro-
vide only a very partial picture of the in£ammatory state
of the airways. A marker of long-term in£ammation,
such as glycosylated protein, which is used to assess
long-term hyperglycemia in diabetes, would be better
as a tool to observe this feature, but such marker has
not been identi¢ed yet in asthma.
In conclusion, airway in£ammationwas of similarmag-
nitude in our groups of asthmatic patients with either
IRAO or CRAO as shown by induced-sputum cell di¡er-
entials although non-smoking patients with IRAO had
more neutrophils than non-smoking patients with
CRAO.Pulmonary function decline over timewas accel-
erated compared to predicted values but was similar in
asthmatic patients with IRAO and in those with CRAO.
Patients with IRAOmay have an increased susceptibility
to develop airway remodeling or other changes leading
to the irreversibility of airway obstruction. Further stu-
dies should look at this possibility.
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